C57BL/6.D2-Tg(EµEBNA1)26Wln/H
| Status | Available to order |
| EMMA ID | EM:15852 |
| Citation information | RRID:IMSR_EM:15852 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | C57BL/6.D2-Tg(EµEBNA1)26Wln/H |
| Alternative name | EµEBNA1.26 |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(EµEBNA1) |
| Gene/Transgene symbol | Tg(EµEBNA1) |
Information from provider
| Provider | Joanna Wilson |
| Provider affiliation | School of Molecular Biosciences, University of Glasgow |
| Genetic information | Transgenic mice harbouring the transgene EµEBNA1, line 26 with the transgene insertion on chromosome 5. |
| Phenotypic information | Homozygous:Lymphoma phenotype as noted for the hemizygous mice. Mice are possibly less robust than hemizygous mice.Heterozygous:Mice carrying the transgene (males and females) develop neoplastic B cell lymphoma with associated leukaemia. The hallmark of the lymphoma is enlargement of the spleen (which can be substantial), and can be accompanied by enlargement of liver and/or lymph nodes (to varying degrees). Occasionally other organ involvement (such as kidney) is noted. The enlarged organs are replete with neoplastic cells. Penetrance is 100%, with mice showing signs of tumour development, typically between the ages of 4 and 12 months (mean 223 days) in strain C57BL/6. The incidence is slightly faster in the BALB/c strain (mean 192 days) and slower in the FVB strain (mean 339 days). |
| Breeding history | The line was generated by DNA microinjection into zygotes (B6D2 F2 zygote background). The mice of this line (denoted 26) were backcrossed to C57BL/6 for over 70 generations. However, the live line was lost during COVID lockdown in 2020 and rederived from frozen embryos that were derived from a cross between male transgenic mice (C57BL/6) to either C57BL/6 or B6D2 F1 females. Since rederivation, the line has again been backcrossed to C57BL/6 strain at least 6 times (both males and females) (as well as inter-crossed with siblings at some generations), making the predicted C57BL/6 contribution to the genome, on average at least 99.22%. The mice are also available as bi-transgenic with the tdTRed transgene (listed separately). |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Literature references
- bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes.;Tsimbouri Penelope, Drotar Mark E, Coy Joanna L, Wilson Joanna B, ;2002;Oncogene;21;5182-7; 12140768
- The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice.;Wilson J B, Levine A J, ;1992;Current topics in microbiology and immunology;182;375-84; 1337032
- Epstein-Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis.;Drotar Mark E, Silva Santiago, Barone Enrico, Campbell Donald, Tsimbouri Penelope, Jurvansu Jaana, Bhatia Pardeep, Klein George, Wilson Joanna B, ;2003;International journal of cancer;106;388-95; 12845679
- Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.;Rühl Julia, Citterio Carmen, Engelmann Christine, Haigh Tracey, Dzionek Andrzej, Dreyer Johannes, Khanna Rajiv, Taylor Graham S, Wilson Joanna B, Leung Carol S, Münz Christian, ;2019;The Journal of clinical investigation;129;2071-2087; 31042161
- Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.;AlQarni Sana, Al-Sheikh Yazeed, Campbell Donald, Drotar Mark, Hannigan Adele, Boyle Shelagh, Herzyk Pawel, Kossenkov Andrew, Armfield Kate, Jamieson Lauren, Bailo Mariarca, Lieberman Paul M, Tsimbouri Penelope, Wilson Joanna B, ;2018;Oncogene;37;3998-4012; 29691476
- Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice.;Wilson J B, Bell J L, Levine A J, ;1996;The EMBO journal;15;3117-26; 8670812
- Epstein-Barr virus nuclear antigen-1 renders lymphocytes responsive to IL-2 but not IL-15 for survival.;Tsimbouri Penelope, Al-Sheikh Yazeed, Drotar Mark E, Cushley William, Wilson Joanna B, ;2008;The Journal of general virology;89;2821-2832; 18931080